Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Site-specific integration

Jonathan B Weitzman

Genome Biology 2002, 3:spotlight-20021022-01  doi:10.1186/gb-spotlight-20021022-01

The electronic version of this article is the complete one and can be found online at:


Published:22 October 2002

© 2002 BioMed Central Ltd

Research news

Controlled integration of exogenous DNA within the genome is an obvious advantage in gene therapy strategies and could circumvent the dangers associated with random genomic integration. In an Advanced Online Publication in Nature Biotechnology, Eric Olivares et al. describe the use of a bacterophage ΦC31 integrase to achieve site-specific integration of therapeutic genes (Nature Biotechnology, 15 October 2002, doi:10.1038/nbt753). The integrase directs recombination between the phage attP site and the host attB site. Olivares et al. tested whether this system could be exploited to deliver therapeutic human genes such as alpha1-antitrypsin (hAAT) or Factor IX (hFIX). The integrase functioned effectively to augment hAAT and hFIX expression in murine livers, and expression levels persisted after partial hepatectomy, suggesting the hFIX had integrated into the genome in liver cells. Olivares et al. confirmed integration and identified two genomic sequences that resemble the attP site and serve as specific integration sites.

References

  1. [http://www.nature.com/nbt] webcite

    Nature Biotechnology

  2. A phage integrase directs efficient site-specific integration in human cells.

    PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL